Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH) Among 4,353 patients, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results